

DAFTAR PUSTAKA

- Azevedo, R. B. *et al.* (2021) 'Covid-19 and the cardiovascular system: a comprehensive review', *Journal of Human Hypertension*, 35(1), pp. 4–11. doi: 10.1038/s41371-020-0387-4.
- Abrishami A, Eslami V, Baharvand Z, Khalili N. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. International Immunopharmacology Epicardial adipose tissue, inflammatory biomarkers and COVID-19: Is there a possible relationship? 2020;(January).
- Azab B, Chainani V, Shah N, McGinn JT. Neutrophil-lymphocyte ratio as a predictor of major adverse cardiac events among diabetic population: a 4-year follow-up study. *Angiology*. 2013;64:456-65.
- B. Cheng, J. Hu, X. Zuo, et al., Predictors of progression from moderate to severe COVID-19: a retrospective cohort, *Clin. Microbiol. Infect.: Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis.* (2020), <https://doi.org/10.1016/j.cmi.2020.06.033>.
- Bihan, H., Heidar, R., Beloeuvre, A. *et al.* Epicardial adipose tissue and severe Coronavirus Disease 19. *Cardiovasc Diabetol* 20, 147 (2021). <https://doi.org/10.1186/s12933-021-01329-z>
- Chong, P. Y. *et al.* (2004) 'Analysis of deaths during the severe acute respiratory syndrome (SARS) epidemic in Singapore: challenges in determining a SARS diagnosis', *Arch Pathol Lab Med*, 128(2), pp. 195–204. doi: 10.1043/1543-2165(2004)128<195:AODDTS>2.0.CO;2.
- Christensen, B. *et al.* (2020) 'Hematology Laboratory Abnormalities in Patients with Coronavirus Disease 2019 (COVID-19)', *Seminars in Thrombosis and Hemostasis*, 46(7), pp. 845–849. doi: 10.1055/s-0040-1715458.
- Cooper, L. T. (2010) 'Myocarditis', *The New England Journal of Medicine*, 11(3), pp. 369–373. Conte C, Esposito A, De Lorenzo R, Di Filippo L, Palmisano A, Vignale D, et al. Epicardial adipose tissue characteristics, obesity and clinical outcomes in COVID-19: A post-hoc analysis of a prospective cohort study. *Nutr Metab Cardiovasc Dis* [Internet]. 2021;31(7):2156–64. Available from: <https://www.sciencedirect.com/science/article/pii/S0939475321001903>
- Das, S. K. (2020) 'The Pathophysiology, Diagnosis and Treatment of Corona Virus Disease 2019 (COVID-19)', *Indian Journal of Clinical Biochemistry*, 35(4), pp. 385–396. doi: 10.1007/s12291-020-00919-0.
- Dhakal, B. P. *et al.* (2020) 'SARS-CoV-2 Infection and Cardiovascular Disease: COVID-19 Heart', *Heart, Lung and Circulation*, 29(January), pp. 973–987. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7135863/pdf/main.pdf>.
- European Society of cardiology (2020) 'ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic', *European heart journal*, pp. 1–115.

- Ghahramani, S. *et al.* (2020) 'Laboratory features of severe vs. non-severe COVID-19 patients in Asian populations: A systematic review and meta-analysis', *European Journal of Medical Research*, 25(1), pp. 1–10. doi: 10.1186/s40001-020-00432-3.
- Grodecki, K. *et al.* (2020) 'Epicardial adipose tissue is associated with extent of pneumonia and adverse outcomes in patients with COVID-19', *Metabolism Clinical and Experimental*, 115(154436), pp. 1–8. doi: <https://doi.org/10.1016/j.metabol.2020.154436>.
- Guan, W. *et al.* (2020) 'Clinical Characteristics of Coronavirus Disease 2019 in China', *New England Journal of Medicine*, 382(18), pp. 1708–1720. doi: 10.1056/nejmoa2002032.
- Guo, J. *et al.* (2020) 'Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection', *Journal of the American Heart Association*, 9(7), p. e016219. doi: 10.1161/JAHA.120.016219.
- Guzik, T. J. *et al.* (2020) 'COVID-19 and the cardiovascular system: Implications for risk assessment, diagnosis, and treatment options', *Cardiovascular Research*, 116(10), pp. 1666–1687. doi: 10.1093/cvr/cvaa106.
- Hemalatha Rajkumar, P. B. (2013) 'The Impact of Obesity on Immune Response to Infection and Vaccine: An Insight into Plausible Mechanisms', *Endocrinology & Metabolic Syndrome*, 02(02). doi: 10.4172/2161-1017.1000113.
- Hendren, N. S. *et al.* (2020) 'Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome', *Circulation*, 141(23), pp. 1903–1914. doi: 10.1161/CIRCULATIONAHA.120.047349.
- Huang, C. *et al.* (2020) 'Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China', *The Lancet*, 395(10223), pp. 497–506. doi: [https://doi.org/10.1016/S0140-6736\(20\)30183-5](https://doi.org/10.1016/S0140-6736(20)30183-5).
- Iacobellis, G. *et al.* (2020) 'Epicardial Fat Inflammation in Severe COVID-19', *Obesity*, 28(12), pp. 2260–2262. doi: 10.1002/oby.23019.
- Iacobellis, G. and Malavazos, A. E. (2020) 'COVID-19 rise in Younger adults with Obesity: Visceral Adiposity can predict the Risk', *Obesity (Silver Spring)*, 10, pp. 0–1. doi: 10.1002/oby.22951.
- Jan, S. *et al.* (2016) 'Bulletin of the World Health Organization Catastrophic health expenditure on acute coronary events in Asia : a prospective study', *Bulletin of the World Health Organization*, 94(November 2015), pp. 1–12. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26966330> <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC4773930>.
- Kementerian Kesehatan Republik Indonesia (2014) *Lingkungan Sehat, Jantung Sehat*. Available at: www.depkes.go.id (Accessed: 8 May 2021).
- Kim, I. (2020) 'Epicardial adipose tissue : fuel for COVID-19- induced cardiac injury?', *European Heart Journal*, 00, pp. 1–2. doi: 10.1002/oby.22831...

- Kimura, K. *et al.* (2019) 'JCS 2018 guideline on diagnosis and treatment of acute coronary syndrome', *Circulation Journal*, 83(5), pp. 1085–1196. doi: 10.1253/circj.CJ-19-0133.
- Kosmeri, C. *et al.* (2020) 'Hematological manifestations of SARS-CoV-2 in children', *Pediatric Blood and Cancer*, 67(12). doi: 10.1002/pbc.28745.
- Liu, F. *et al.* (2020) 'Prognostic value of interleukin-6, C-reactive protein, and procalcitonin inpatients with COVID-19', *Journal of Clinical Virology*, 127(104370), pp. 1–5. doi: 10.1016/j.jcv.2020.104370.
- Liu K, Wang X, Song G. Association of epicardial adipose tissue with the severity and adverse clinical outcomes of COVID-19: A meta-analysis. *Int J Infect Dis* [Internet]. 2022;120:33–40. Available from: <https://www.sciencedirect.com/science/article/pii/S1201971222002120>
- Liu, X., Zhang, R. and He, G. (2020) 'Hematological findings in coronavirus disease 2019: indications of progression of disease', *Annals of Hematology*, 99(7), pp. 1421–1428. doi: 10.1007/s00277-020-04103-5.
- Liu Y, Du X, Chen J, Jin Y, Peng L, Wang HHX, *et al.* Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. *J Infect*. 2020; 17(28): 1-7.
- Luo, X. *et al.* (2020) 'Prognostic value of C-reactive protein in patients with COVID-19', *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America*, 71(16), pp. 2174–2179. doi: 10.1093/cid/ciaa641.
- Madjid, M. *et al.* (2020) 'Potential Effects of Coronaviruses on the Cardiovascular System: A Review', *JAMA Cardiology*, pp. 831–840. doi: 10.1001/jamacardio.2020.1286.
- Mehta, R., Bello-Chavolla, O.Y., Mancillas-Adame, L. *et al.* Epicardial adipose tissue thickness is associated with increased COVID-19 severity and mortality. *Int J Obes* **46**, 866–873 (2022). <https://doi.org/10.1038/s41366-021-01050-7>
- Makki, N., Brennan, T. M. and Girotra, S. (2015) 'Acute coronary syndrome', *Journal of Intensive Care Medicine*, 30(4), pp. 186–200. doi: 10.1177/0885066613503294.
- Malavazos, A. E., Goldberger, J. J. and Iacobellis, G. (2020) 'Does epicardial fat contribute to COVID-19 myocardial inflammation?', *European Heart Journal*, 41(24), p. 2333. doi: 10.1093/eurheartj/ehaa471.
- Mihardja, L. *et al.* (2013) *Penyakit Tidak Menular*. Jakarta: Kementerian Kesehatan Republik Indonesia.
- Montalescot, G. (2007) 'On behalf of the OPERA investigators. STEMI and NSTEM I are two distinct pathophysiological entities: reply', *Eur Heart J*, 21, pp. 2685–6.
- Mousavizadeh, L. and Ghasemi, S. (2020) 'Genotype and phenotype of COVID-19: Their roles in pathogenesis', *Journal of Microbiology, Immunology and Infection*, (xxxx), pp. 0–4. doi: 10.1016/j.jmii.2020.03.022.

- Ornelas-Ricardo, D. and Jaloma-Cruz, A. R. (2020) 'Coronavirus Disease 2019: Hematological Anomalies and Antithrombotic Therapy', *The Tohoku journal of experimental medicine*, 251(4), pp. 327–336. doi: 10.1620/tjem.251.327.
- Ponti, G. *et al.* (2020) 'Biomarkers associated with COVID-19 disease progression', *Critical Reviews in Clinical Laboratory Sciences*, 0(0), pp. 1–11. doi: 10.1080/10408363.2020.1770685.
- Pimentel GD, Dela MCM, Laviano A. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information. 2020;(January).
- Qu, R. *et al.* (2020) 'Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19', *Journal of Medical Virology*, 92(9), pp. 1533–1541. doi: 10.1002/jmv.25767.
- Rilantono and Rahajoe (2014) *Penyakit Kardiovaskular pada Perempuan : Tantangan Abad Ke-21*. Jakarta: Badan Penerbit Fakultas Kedokteran Universitas Indonesia.
- Rossi, A.P., Donadello, K., Schweiger, V. *et al.* Epicardial adipose tissue volume and CT-attenuation as prognostic factors for pulmonary embolism and mortality in critically ill patients affected by COVID-19. *Eur J Clin Nutr* (2022). <https://doi.org/10.1038/s41430-022-01197-0>
- Ryan, P. M. D. and Caplice, N. M. (2020) 'Is Adipose Tissue a Reservoir for Viral Spread, Immune Activation, and Cytokine Amplification in Coronavirus Disease 2019?', *Obesity*, 28(7), pp. 1191–1194. doi: 10.1002/oby.22843.
- Rychter, A. M. *et al.* (2020) 'Should patients with obesity be more afraid of COVID-19?', *Obesity Reviews*, 21(9), pp. 1–8. doi: 10.1111/obr.13083.
- Sahua, B. R. *et al.* (2020) 'C-reactive protein: A promising biomarker for poor prognosis in COVID-19 infection', *Clinica chimica acta; international journal of clinical chemistry*, 509, pp. 91–94. doi: 10.1016/j.cca.2020.06.013.
- Schiavone, M. *et al.* (2020) 'Acute Coronary Syndromes and Covid-19: Exploring the Uncertainties', *Journal of Clinical Medicine*, 9(6), p. 1683. doi: 10.3390/jcm9061683. Simadibrata DM, Calvin J, Wijaya AD, Arkan N, Ibrahim A. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information. 2020;(January).
- Sevilla T, Aparisi-Sanz Á, Aristizábal-Duque C, Gómez-Salvador I, Baladrón C, San Román A. Epicardial adipose tissue attenuation in admitted patients with COVID-19. *Rev Española Cardiol (English Ed [Internet]*. 2022;75(1):98–100. Available from: <https://www.revespcardiol.org/en-epicardial-adipose-tissue-attenuation-in-articulo-S188558572100222X>
- Sukrisman L, Sinto R, Priantono D. Hematologic Profiles and Correlation Between Absolute Lymphocyte Count and Neutrophil/Lymphocyte Ratio with Markers of Inflammation of COVID-19 in an Indonesian National Referral Hospital. *Int J Gen*

Med. 2021;14:6919-6924.



- Tajbakhsh, A. *et al.* (2021) *COVID-19 and cardiac injury: clinical manifestations, biomarkers, mechanisms, diagnosis, treatment, and follow up, Expert Review of Anti-Infective Therapy.* Taylor & Francis. doi: 10.1080/14787210.2020.1822737.
- Wang, D. *et al.* (2020) 'Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China', *JAMA - Journal of the American Medical Association*, 323(11), pp. 1061–1069. doi: 10.1001/jama.2020.1585.
- Wei, Z. *et al.* (2021) 'Pre-existing Health Conditions and Epicardial Adipose Tissue Volume : Potential Risk Factors for Myocardial Injury in COVID-19 Patients', 7, pp. 1–10. doi: 10.3389/fcvm.2020.585220.
- World Health Organization (2017) *World Heart Day 2017.* Available at: http://www.who.int/cardiovascular_diseases/world-heart-day-2017 (Accessed: 8 May 2021).
- Yamada, T. *et al.* (2020) 'Value of leukocytosis and elevated C-reactive protein in predicting severe coronavirus 2019 (COVID-19): A systematic review and meta-analysis', *Clinica Chimica Acta*, 509, pp. 235–243. doi: 10.1016/j.cca.2020.06.008.
- Yang, A.P., Liu, J., Tao, W., & Li, H.M. (2020). The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. *International immunopharmacology*, 106504. doi: <https://doi.org/10.1016/j.intimp.2020.106504>
- Ye, W. *et al.* (2020) 'Dynamic changes of D-dimer and neutrophil-lymphocyte count ratio as prognostic biomarkers in COVID-19', *Respiratory Research*, 21(1), pp. 1–7. doi: 10.1186/s12931-020-01428-7.
- Zhao, Y. *et al.* (2021) 'COVID-19 letter to the editor: Epicardial fat inflammation as possible enhancer in COVID-19?', *Metabolism: clinical and experimental*, 117, p. 154722. doi: 10.1016/j.metabol.2021.154722.
- Zheng, Y.-Y. *et al.* (2019) 'COVID-19 and the cardiovascular system', *Nature Reviews Cardiology*. doi: 10.1038/s41569-020-0360-5.

REKOMENDASI PERSETUJUAN ETIK

Nomor : 519/UN4.6.4.5.31/ PP36/ 2022

Tanggal: 16 September 2022

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH22070386		No Sponsor	
Peneliti Utama	dr. Hasnawiah		Sponsor	
Judul Peneliti	Hubungan Rasio Neutrofil Limfosit Terhadap densitas Lemak Epikardial Pada Pasien Pneumonia Corona Virus Disease-19 derajat sedang dan derajat berat yang disertai			
No Versi Protokol	2	Tanggal Versi	6 September 2022	
No Versi PSP	2	Tanggal Versi	6 September 2022	
Tempat Penelitian	RSUP Dr. Wahidin Sudirohusodo Makassar			
Jenis Review	<input type="checkbox"/> Exempted <input checked="" type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal		Masa Berlaku	Frekuensi review lanjutan
			16 September 2022 sampai 16 September 2023	
Ketua KEP Universitas Hasanuddin	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)		Tanda tangan 	
Sekretaris KEP Universitas Hasanuddin	Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)		Tanda tangan 	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapo SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan



KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN
FAKULTAS KEDOKTERAN

Jl. Perintis Kemerdekaan Kampus Tamalanrea Km. 10 Makassar 90245 Telp. (0411) 5077912, 586010 (0411) 586200
Fax. 586010 Email : fkunhas@med.unhas.ac.id

SURAT KEPUTUSAN
DEKAN FAKULTAS KEDOKTERAN UNIVERSITAS HASANUDDIN
No.257/UN4.6.1/KEP/2023

TENTANG
PENGANGKATAN PEMBIMBING SEMINAR USUL, HASIL DAN UJIAN AKHIR BAGI MAHASISWA
Sdr. : dr. HASNAWIAH NOMOR POKOK : C165181001
PROGRAM PENDIDIKAN DOKTER SPESIALIS ILMU PENYAKIT JANTUNG DAN PEMBULUH
DARAH
FAKULTAS KEDOKTERAN UNIVERSITAS HASANUDDIN

DEKAN FAKULTAS KEDOKTERAN UNIVERSITAS HASANUDDIN

- Membaca : Surat Program Pendidikan Dokter Spesialis **Ilmu Penyakit Jantung dan Pembuluh Darah** Fakultas Kedokteran Unhas Nomor : 096/UN4.6.8/PK.03.00/2023 tanggal 02 Januari 2023 perihal SK Pembimbing Karya Akhir bagi Sdr. **dr. Hasnawiah** dengan Judul Penelitian: "**Hubungan Rasio Nutrofil Limfosit dengan Densitas Lemak Epikardial Pada Pasien Sindrom Koroner Akut yang disertai Infeksi COVID-19**"
- Menimbang : a. Bahwa dalam rangka pelaksanaan Bimbingan Karya Akhir bagi Sdr. **dr. Hasnawiah** Mahasiswa Program Pendidikan Dokter Spesialis **Ilmu Penyakit Jantung dan Pembuluh Darah** Fakultas Kedokteran Universitas Hasanuddin, dipandang perlu mengangkat Tim Pembimbing Karya Akhir
b. Bahwa untuk keperluan huruf (a) di atas, maka dipandang perlu menerbitkan surat Keputusannya.
- Mengingat : 1. Keputusan Rektor Unhas No. 977/J04/O/2005
2. Keputusan Rektor Unhas No. 2283/H4/P/2007
3. Keputusan Rektor Unhas No. 1784/H4.2/K/2010
4. Keputusan Rektor Unhas No. 1282/H4.2/K/2011
5. Keputusan Rektor Unhas No. 8650/UN4.2/KU.10/2012
6. Keputusan Rektor Unhas No. 8765/UN4.2/KU.10/2013

MEMUTUSKAN

- Menetapkan :
Pertama : Membentuk Tim Pembimbing Karya Akhir bagi Sdr. **dr. Hasnawiah** Mahasiswa Program Pendidikan Dokter Spesialis **Ilmu Penyakit Jantung dan Pembuluh Darah** Fakultas Kedokteran Universitas Hasanuddin dengan susunan sebagai berikut :
- | | |
|---|-----------------------|
| 1. Prof. Dr. dr. Ali Aspar Mappahya, Sp.PD(K), Sp.JP(K) | Pembimbing Utama |
| 2. Dr. dr. Muzakkir Amir, Sp.JP(K) | Pembimbing Pendamping |
| 3. Dr. dr. Irawaty Djaharuddin, Sp.P(K) | Pembimbing Pendamping |
| 4. dr. Nikmatia Latief, Sp.Rad(K) | Pembimbing Pendamping |
| 5. Dr. dr. Andi Alfian Zainuddin, M.KM | Pembimbing Pendamping |
- Kedua : Segala biaya yang timbul sehubungan dengan Surat Keputusan ini dibebankan pada Anggaran DPA PTN Badan Hukum Tahun 2023 alokasi Fakultas Kedokteran Universitas Hasanuddin.
- Ketiga : Surat Keputusan ini berlaku terhitung mulai tanggal ditetapkannya, dengan ketentuan apabila dikemudian hari ternyata terdapat kesalahan atau kekeliruan didalamnya akan diadakan perbaikan sebagaimana mestinya.

Ditetapkan di : Makassar
Pada tanggal ^{BURU} 05 Januari 2023

a.n Dekan
Wakil Dekan Bidang Akademik dan Kemahasiswaan

dr. Agussalim Bukhari, M.Clin.Med., Ph.D., Sp.GK(K)
NIP. 197008211999031001

Tembusan :

1. Ketua Program Studi **Ilmu Penyakit Jantung dan Pembuluh Darah**
2. Masing-masing yang bersangkutan untuk dilaksanakan
3. **dr. Hasnawiah**

Group Statistics					
Severitas Covid		N	Mean	Std. Deviation	Std. Error Mean
AVG Dextra	1	22	-69,45	13,273	2,830
	0	41	-112,27	22,627	3,534
AVG Sinistra	1	22	-66,86	12,781	2,725
	0	41	-135,85	160,880	25,125
AVG IV	1	22	-72,41	14,077	3,001
	0	41	-101,68	41,354	6,458

Independent Samples Test											
		Levene's Test for Equality of Variances		t-test for Equality of Means						95% Confidence Interval of the Difference	
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	Lower	Upper	
AVG Dextra	Equal variances assumed	4,617	0,036	8,137	61	0,000	42,814	5,262	32,292	53,335	
	Equal variances not assumed			9,457	60,423	0,000	42,814	4,527	33,759	51,868	
AVG Sinistra	Equal variances assumed	1,575	0,214	2,000	61	0,050	68,990	34,487	0,029	137,951	
	Equal variances not assumed			2,730	40,936	0,009	68,990	25,273	17,949	120,032	
AVG IV	Equal variances assumed	1,955	0,167	3,212	61	0,002	29,274	9,115	11,047	47,501	
	Equal variances not assumed			4,111	54,316	0,000	29,274	7,122	14,998	43,550	

Area Under the Curve						
Test Result Variable(s)	Area	Std. Error ^a	Asymptotic Sig. ^b	Asymptotic 95% Confidence Interval		
				Lower Bound	Upper Bound	
AVG Dextra	0,959	0,021	0,000	0,918	1,000	
AVG Sinistra	0,953	0,023	0,000	0,908	0,999	
AVG IV	0,882	0,042	0,000	0,800	0,964	

Correlations						
			AVG Dextra	AVG Sinistra	AVG IV	NLR
Spearman's rho	AVG Dextra	Correlation Coefficient	1,000	.833**	.693**	.670**
		Sig. (2-tailed)		0,000	0,000	0,000
		N	63	63	63	63
	AVG Sinistra	Correlation Coefficient	.833**	1,000	.719**	.685**
		Sig. (2-tailed)	0,000		0,000	0,000
		N	63	63	63	63
	AVG IV	Correlation Coefficient	.693**	.719**	1,000	.602**
		Sig. (2-tailed)	0,000	0,000		0,000
		N	63	63	63	63
	NLR	Correlation Coefficient	.670**	.685**	.602**	1,000
		Sig. (2-tailed)	0,000	0,000	0,000	
		N	63	63	63	63

Area Under the Curve						
Test Result Variable(s)	Area	Std. Error ^a	Asymptotic Sig. ^b	Asymptotic 95% Confidence Interval		
				Lower Bound	Upper Bound	
AVG Dextra	0,846	0,057	0,000	0,734	0,959	
AVG Sinistra	0,865	0,053	0,000	0,762	0,967	
AVG IV	0,848	0,047	0,000	0,755	0,940	